Bionomics Limited Release: BNC105 Phase I/II Trial Achieves A High Response Rate In Ovarian Cancer
ADELAIDE, South Australia, Feb. 3, 2014 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) (ADR:BMICY) has received positive results in the Phase I clinical trial of its cancer drug candidate BNC105 in women with ovarian cancer.
Help employers find you! Check out all the jobs and post your resume.